Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Delito (rituximab biosimilar)
i
Other names:
TQB2303, TQB 2303
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Sino Biopharm
Drug class:
CD20 inhibitor
Related drugs:
‹
rituximab (176)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
IMM0306 (2)
IGM-2323 (2)
mosunetuzumab-axgb (2)
AR160 (2)
rituximab-arrx (2)
glofitamab-gxbm (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
AcellBia (rituximab biosimilar) (0)
ACTR087 (0)
ALETA-001 (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
obinutuzumab-β (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CND261 (0)
DI Leu16 IL-2 (0)
IGN002 (0)
F007 (rituximab biosimilar) (0)
GB241 (rituximab biosimilar) (0)
GSK5926371 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
AME-133v (0)
ocrelizumab (0)
XmAb13676 (0)
PRO131921 (0)
PRO-203 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
TG20 (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
rituximab (176)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
IMM0306 (2)
IGM-2323 (2)
mosunetuzumab-axgb (2)
AR160 (2)
rituximab-arrx (2)
glofitamab-gxbm (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
AcellBia (rituximab biosimilar) (0)
ACTR087 (0)
ALETA-001 (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
obinutuzumab-β (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CND261 (0)
DI Leu16 IL-2 (0)
IGN002 (0)
(0)
GB241 (rituximab biosimilar) (0)
GSK5926371 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
AME-133v (0)
ocrelizumab (0)
XmAb13676 (0)
PRO131921 (0)
PRO-203 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
TG20 (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
trastuzumab + TQB2303 (rituximab biosimilar)
Sensitive: C3 – Early Trials
trastuzumab + TQB2303 (rituximab biosimilar)
Sensitive
:
C3
trastuzumab + TQB2303 (rituximab biosimilar)
Sensitive: C3 – Early Trials
trastuzumab + TQB2303 (rituximab biosimilar)
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.